| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Detected but not Quantified |
|---|
| Creation Date | 2006-05-18 08:31:29 UTC |
|---|
| Update Date | 2022-09-22 18:34:16 UTC |
|---|
| HMDB ID | HMDB0001922 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Clotrimazole |
|---|
| Description | Clotrimazole is an imidazole derivative with a broad spectrum of antimycotic activity. It inhibits biosynthesis of the sterol ergostol, an important component of fungal cell membranes. Its action leads to increased membrane permeability and apparent disruption of enzyme systems bound to the membrane. -- Pubchem; There is the potential for drug interactions with Clotrimazole if taken orally, as it is a potent, specific inhibitor of cytochrome P450 oxidase enzymes and so may alter the metabolism of other drugs. Clotrimazole is an antifungal medication commonly used in the treatment of fungal infections of both humans and animals such as vaginal yeast infections and ringworm. -- Wikipedia ; An imidazole derivative with a broad spectrum of antimycotic activity. It inhibits biosynthesis of the sterol ergostol, an important component of fungal cell membranes. Its action leads to increased membrane permeability and apparent disruption of enzyme systems bound to the membrane. Clotrimazole is a potent, specific inhibitor of cytochrome P450 oxidase enzymes. Hence, it may alter the metabolism of other drugs particularly if taken orally. -- Wikipedia ; Clotrimazole is an antifungal medication commonly used in the treatment of fungal infections of both humans and animals such as vaginal yeast infections and ringworm. It also used to treat athlete's foot and jock itch. |
|---|
| Structure | ClC1=CC=CC=C1C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1 InChI=1S/C22H17ClN2/c23-21-14-8-7-13-20(21)22(25-16-15-24-17-25,18-9-3-1-4-10-18)19-11-5-2-6-12-19/h1-17H |
|---|
| Synonyms | | Value | Source |
|---|
| 1-((2-Chlorophenyl)diphenylmethyl)-1H-imidazole | ChEBI | | 1-(alpha-(2-Chlorophenyl)benzhydryl)imidazole | ChEBI | | 1-(O-Chloro-alpha,alpha-diphenylbenzyl)imidazole | ChEBI | | 1-(O-Chlorotrityl)imidazole | ChEBI | | Lotrimin | ChEBI | | Mycelex | ChEBI | | 1-(a-(2-Chlorophenyl)benzhydryl)imidazole | Generator | | 1-(Α-(2-chlorophenyl)benzhydryl)imidazole | Generator | | 1-(O-Chloro-a,a-diphenylbenzyl)imidazole | Generator | | 1-(O-Chloro-α,α-diphenylbenzyl)imidazole | Generator | | (Chlorotrityl)imidazole | HMDB | | Canesten | HMDB | | Canesten 1-day cream combi-pak | HMDB | | Canesten 1-day therapy | HMDB | | Canesten 3-day therapy | HMDB | | Canesten 6-day therapy | HMDB | | Canesten combi-pak 1-day therapy | HMDB | | Canesten combi-pak 3-day therapy | HMDB | | Canesten cream | HMDB | | Canesten solution | HMDB | | Canestine | HMDB | | Chlotrimazole | HMDB | | Clotrimaderm | HMDB | | Clotrimaderm cream | HMDB | | Clotrimazol | HMDB | | Clotrimazolum | HMDB | | Desamix F | HMDB | | Empecid | HMDB | | Fem care | HMDB | | FemCare | HMDB | | Gyne lotrimin | HMDB | | Gyne-lotrimin | HMDB | | Gyne-lotrimin 3 | HMDB | | Gyne-lotrimin 3 combination pack | HMDB | | Gyne-lotrimin combination pack | HMDB | | Gyne-lotrimin3 | HMDB | | Gyne-lotrimin3 combination pack | HMDB | | Gynix | HMDB | | Lopac-C-6019 | HMDB | | Lotrimax | HMDB | | Lotrimin af | HMDB | | Lotrimin af cream | HMDB | | Lotrimin af jock-itch cream | HMDB | | Lotrimin af lotion | HMDB | | Lotrimin af solution | HMDB | | Lotrimin cream | HMDB | | Lotrimin lotion | HMDB | | Lotrimin solution | HMDB | | Lotrisone | HMDB | | mono-Baycuten | HMDB | | Monobaycuten | HMDB | | Mycelax | HMDB | | Mycelex 7 | HMDB | | Mycelex cream | HMDB | | Mycelex g | HMDB | | Mycelex otc | HMDB | | Mycelex solution | HMDB | | Mycelex troches | HMDB | | Mycelex twin pack | HMDB | | Mycelex-7 | HMDB | | Mycelex-7 combination pack | HMDB | | Mycelex-g | HMDB | | Mycelex: mycosporinrimazole | HMDB | | Myclo cream | HMDB | | Myclo solution | HMDB | | Myclo spray solution | HMDB | | Myclo-gyne | HMDB | | Mycosporin | HMDB | | Mykosporin | HMDB | | Neo-zol cream | HMDB | | Otomax | HMDB | | Pedisafe | HMDB | | Prestwick_120 | HMDB | | Rimazole | HMDB | | Tibatin | HMDB | | Trimysten | HMDB | | Trivagizole 3 | HMDB | | Veltrim | HMDB | | Klotrimazole | HMDB | | Schering brand OF clotrimazole | HMDB | | Bayer brand 1 OF clotrimazole | HMDB | | Bayer brand 2 OF clotrimazole | HMDB | | FB b 5097 | HMDB | | Bay b 5097 | HMDB | | Clotrimazole schering brand | HMDB | | Kanesten | HMDB |
|
|---|
| Chemical Formula | C22H17ClN2 |
|---|
| Average Molecular Weight | 344.837 |
|---|
| Monoisotopic Molecular Weight | 344.108026261 |
|---|
| IUPAC Name | 1-[(2-chlorophenyl)diphenylmethyl]-1H-imidazole |
|---|
| Traditional Name | clotrimazole |
|---|
| CAS Registry Number | 23593-75-1 |
|---|
| SMILES | ClC1=CC=CC=C1C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1 |
|---|
| InChI Identifier | InChI=1S/C22H17ClN2/c23-21-14-8-7-13-20(21)22(25-16-15-24-17-25,18-9-3-1-4-10-18)19-11-5-2-6-12-19/h1-17H |
|---|
| InChI Key | VNFPBHJOKIVQEB-UHFFFAOYSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as triphenyl compounds. These are aromatic compounds containing a triphenyl moiety. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Benzenoids |
|---|
| Class | Triphenyl compounds |
|---|
| Sub Class | Not Available |
|---|
| Direct Parent | Triphenyl compounds |
|---|
| Alternative Parents | |
|---|
| Substituents | - Triphenyl compound
- Chlorobenzene
- Halobenzene
- Aryl chloride
- Aryl halide
- Monocyclic benzene moiety
- N-substituted imidazole
- Azole
- Heteroaromatic compound
- Imidazole
- Azacycle
- Organoheterocyclic compound
- Organonitrogen compound
- Organic nitrogen compound
- Hydrocarbon derivative
- Organopnictogen compound
- Organochloride
- Organohalogen compound
- Aromatic heteromonocyclic compound
|
|---|
| Molecular Framework | Aromatic heteromonocyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Physiological effect | |
|---|
| Disposition | |
|---|
| Process | Not Available |
|---|
| Role | |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | 148 °C | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | Not Available | Not Available | | LogP | Not Available | Not Available |
|
|---|
| Experimental Chromatographic Properties | Not Available |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 9.74 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 14.5608 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 1.57 minutes | 32390414 | | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 29.8 seconds | 40023050 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 2877.7 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 467.4 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 211.2 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 263.0 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 319.0 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 637.1 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 777.0 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 67.9 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 1585.9 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 592.0 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1394.1 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 456.9 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 415.7 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 293.6 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 40.6 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 8.1 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatized |
|---|
| General References | - Schmook FP, Meingassner JG, Billich A: Comparison of human skin or epidermis models with human and animal skin in in-vitro percutaneous absorption. Int J Pharm. 2001 Mar 14;215(1-2):51-6. [PubMed:11250091 ]
- Lucker PW, Beubler E, Kukovetz WR, Ritter W: Retention time and concentration in human skin of bifonazole and clotrimazole. Dermatologica. 1984;169 Suppl 1:51-5. [PubMed:6526092 ]
- Schmidt A, Ruhl-Horster B: In vitro susceptibility of Malassezia furfur against azole compounds. Mycoses. 1996 Jul-Aug;39(7-8):309-12. [PubMed:9009652 ]
|
|---|